Dr. Clancy L. Cone

Internal Medicine
2825 Ft Missoula Rd, 
Missoula, MT 
2825 Ft Missoula Rd, 
Missoula, MT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Clancy Cone is a primary care provider, practicing in Internal Medicine in Missoula, Montana. Dr. Cone is rated as an Experienced provider by MediFind in the treatment of Gout. His top areas of expertise are Familial Hemiplegic Migraine, Migraine with Brainstem Aura, High Cholesterol, and Hypertension.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in MT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2825 Ft Missoula Rd, Missoula, MT 59804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Combination product
Study Drugs: Abaloparatide solid microstructured transdermal system, Abaloparatide subcutaneous
Study Phase: Phase 3
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
View 5 Less Clinical Trials

1 Total Publications

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
Journal: JAMA network open
Published: October 12, 2021
Similar Doctors
Experienced in Gout
Dr. Peter C. Szekely
Internal Medicine
Experienced in Gout
Dr. Peter C. Szekely
Internal Medicine

Providence Health And Services Mt

500 W Broadway St, Suite 310, 
Missoula, MT 
 (3.0 miles away)
406-728-6520
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Szekely is a primary care provider, practicing in Internal Medicine in Missoula, Montana. Dr. Szekely is rated as an Advanced provider by MediFind in the treatment of Gout. His top areas of expertise are Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, and Diabetic Hyperglycemic Hyperosmolar Syndrome. Dr. Szekely is currently accepting new patients.

Experienced in Gout
Dr. Kevin M. Sheehan
Internal Medicine
Experienced in Gout
Dr. Kevin M. Sheehan
Internal Medicine
500 West Broadway Street, Floor 4, 
Missoula, MT 
 (3.0 miles away)
406-327-1900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Sheehan is a primary care provider, practicing in Internal Medicine in Missoula, Montana. Dr. Sheehan is rated as an Advanced provider by MediFind in the treatment of Gout. His top areas of expertise are Hypertension, Glucocorticoid-Remediable Aldosteronism, Familial Hypertension, and Chronic Cough.

Experienced in Gout
Dr. Clare L. Brownlee
Internal Medicine
Experienced in Gout
Dr. Clare L. Brownlee
Internal Medicine

Rchp Billings - Missoula LLC

2831 Fort Missoula Rd, 
Missoula, MT 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Clare Brownlee is a primary care provider, practicing in Internal Medicine in Missoula, Montana. Dr. Brownlee is rated as an Advanced provider by MediFind in the treatment of Gout. Her top areas of expertise are Pulmonary Veno-Occlusive Disease, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Postmenopausal Osteoporosis. Dr. Brownlee is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cone's expertise for a condition
ConditionClose
      View All 27 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile